A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus

Journal of Diabetes Science and Technology

Volumn 8, Issue 3, 2014, Pages 551-559

  Geho, W Blair ^a   Rosenberg, Len N ^a   Schwartz, Sherwyn L ^b   Lau, John R ^a   Gana, Theophilus J ^c  

^a Diasome Pharmaceuticals Inc   (United States)

^b Diabetes and Glandular Disease Research Center   (United States)

^c Biopharmatech Consulting Inc   (United States)

Author keywords

Dose response; Hepatic directed vesicle insulin; Insulin delivery system; Oral; Postprandial plasma glucose; Type 2 diabetes

Indexed keywords

BIOTIN; GLUCOSE; HEMOGLOBIN A1C; HEPATIC DIRECTED VESICLE INSULIN; INSULIN; LIPID; METFORMIN; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; PLACEBO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; MICROCAPSULE;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN TREATMENT; LEFT EAR ITCHING; LIVER CELL; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CONCENTRATION-TIME CURVE; POSTPRANDIAL STATE; SINGLE BLIND PROCEDURE; TEST MEAL; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MICROCAPSULE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TEXAS; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BIOMARKERS; BLOOD GLUCOSE; CAPSULES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NANOPARTICLES; SINGLE-BLIND METHOD; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900821501     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814524871     Document Type: Article

References (30)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012. (Pubitemid 29254858)
4. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25(2):330-336. [Erratum in: Diabetes Care. 2002;25(7):1268.] (Pubitemid 41079631)
5. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20(3):292-298. (Pubitemid 27098212)
6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(suppl 3):S18-S24. (Pubitemid 35034478)
7. Peyrot M, Rubin RR, Lauritzen T, et al. The International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679. (Pubitemid 43951158)
8. Heinemann L, Pfützner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des. 2001;7(14):1327- 1351. (Pubitemid 32798814)
9. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetes Med. 2003;20(11):886-898. (Pubitemid 41701487)
10. Arbit E, Kidron M. Oral Insulin: the rationale for this approach and current development. J Diabetes Sci Technol. 2009;3(3):562-567.
11. Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol. 2009;3(3):568-584.
12. Geho WB, Geho HC, Lau J, Gana TJ. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol. 2009;3(6):1451-1459.
13. Davis SN, Geho B, Tate D, Galassetti P, Lau J, Granner D, Mann S. The effects of HDV-insulin on carbohydrate metabolism in Type 1 diabetic patients. J Diabetes Complications. 2001;15(5):227-233. (Pubitemid 32750609)
14. Geho B, Lau J, Rosenberg L. Hepatic-directed vesicle-insulin: evaluation of a novel oral and subcutaneous insulin delivery system in animal models of diabetes (Abstract). Diabetes. 2008;57(suppl 1):A126.
15. Schwartz S, Geho B, Rosenberg L, Lau J. A 2-week randomized, active comparator study of two HDV-Insulin routes (SC and oral) and SC human insulin in patients with type 1 diabetes mellitus (Abstract). Diabetes. 2008;57(suppl 1):A124.
16. Blackard WG, Nelson NC. Portal and peripheral vein immunoreactive insulin concentrations before and after glucose infusion. Diabetes. 1970;19(5):302-306.
17. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol. 1983;244(6):E517-E527. (Pubitemid 13067061)
18. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005;54(6):1649-1656. (Pubitemid 40770754)
19. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 1975;55(6):1278-1283. (Pubitemid 8036490)
20. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34(3):222-234. (Pubitemid 15134779)
21. Shishko PI, Kovalev PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes. 1992;41(9):1042-1049.
22. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 pt 2):97-103. (Pubitemid 26011604)
23. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1982;23(4):313-319. (Pubitemid 12020666)
24. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607. (Pubitemid 19004941)
25. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97(10):996-1001. (Pubitemid 28125472)
26. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(suppl 11):S3109-S3120.
27. Geho B, Lau J, Rosenberg L, Schwartz S. A single-blind, placebo-controlled, food-dose timing trial of oral HDV-Insulin in patients with type 2 diabetes mellitus. Diabetes. 2009;58(suppl 1):A112.
28. Field JB. Insulin extraction by the liver. Ann Rev Med. 1973;24:309-314.
29. Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab. 1983;56(6):1294-1300. (Pubitemid 13055128)
30. Bratusch-Marrain PR, Waldhäusl WK, Gasić S, Hofer A. Hepatic disposal of biosynthetic human insulin and porcine C-peptide in humans. Metabolism. 1984;33(2):151-157. (Pubitemid 14185410)